A senior industry executive with knowledge of B. Riley Financial confirmed to InvestmentNews on Monday that plans to split ...

B. Riley Securities Inc. has reached an agreement to end litigation that spanned two states with one its former top ...

B. Riley Securities has recently initiated Nektar Therapeutics (NKTR) stock to Buy rating, as announced on January 8, 2025, according to Finviz. Earlier, on December 10, 2024, H.C ...

BlackRock (BLK) disclosed a 5.1% passive stake in B. Riley Financial (RILY), which represents 1.54M shares. The filing with the SEC does not ...

On Tuesday, Fabrinet (FN) stock saw a decline, ending the day at $207.13 which represents a decrease of $-18.47 or -8.19% from the prior close of $225.6. The stock opened at $205.66 and touched a low ...

B. Riley lowered the firm’s price target on Gentex (GNTX) to $32.50 from $37 and keeps a Buy rating on the shares following the Q4 report. The firm expects both the company’s sales and gross margin ...

B. Riley Financial Inc., seeking to recover from soured investments and a string of losses, has briefed its staff on a tentative plan to spin off its securities business into a separate company.

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

Investment analysts at B. Riley issued their FY2027 earnings per share (EPS) estimates for GCT Semiconductor in a research note issued to investors on Monday, February 3rd. B. Riley analyst C. Ellis ...

B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on the company’s strategy to inactivate or degrade ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...